Masters Capital Management LLC Gilead Sciences, Inc. Call Options Transaction History

Masters Capital Management LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $41 Million - $51.7 Million	615,000 Added 159.74%	1,000,000 $83.8 Million
Q2 2024 Aug 14, 2024	BUY	$63.15 - $72.88 $24.3 Million - $28.1 Million	385,000 New	385,000 $26.4 Million
Q1 2022 May 16, 2022	BUY	$57.92 - $72.58 $23.2 Million - $29 Million	400,000 Added 66.67%	1,000,000 $59.5 Million
Q4 2021 Feb 14, 2022	BUY	$64.88 - $73.64 $6.49 Million - $7.36 Million	100,000 Added 20.0%	600,000 $43.6 Million
Q3 2021 Nov 15, 2021	SELL	$67.69 - $73.03 $33.8 Million - $36.5 Million	-500,000 Reduced 50.0%	500,000 $34.9 Million
Q1 2021 May 17, 2021	BUY	$60.0 - $68.46 $60 Million - $68.5 Million	1,000,000 New	1,000,000 $64.6 Million
Q4 2018 Feb 12, 2019	SELL	$60.54 - $79.0 $60.5 Million - $79 Million	-1,000,000 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $36.7 Million - $40.6 Million	514,500 Added 105.97%	1,000,000 $77.2 Million
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $98.3 Million - $115 Million	-1,514,500 Reduced 75.73%	485,500 $34.4 Million
Q3 2017 Nov 14, 2017	BUY	$72.11 - $85.47 $144 Million - $171 Million	2,000,000	2,000,000 $162 Million

1,926

992M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $118B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Masters Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Masters Capital Management LLC with notifications on news.